AMP945 + nab-paclitaxel + gemcitabine

AMP945 + nab-paclitaxel + gemcitabine is a combination therapy under investigation for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma. - **AMP945 (narmafotinib)** is an orally bioavailable small molecule inhibitor targeting focal adhesion kinase (FAK), a kinase implicated in tumor growth, metastasis, fibrosis, and chemoresistance due to its roles in the tumor microenvironment. - **nab-paclitaxel (Abraxane)** is a nanoparticle albumin-bound formulation of the chemotherapy paclitaxel, which works by inhibiting microtubule depolymerization, leading to cell death, and is used as a standard-of-care agent for various cancers. - **gemcitabine** is a nucleoside analog that inhibits DNA synthesis, leading to cell death, and is standard-of-care in pancreatic cancer. This drug combination is being investigated to determine if priming tumors with the FAK inhibitor AMP945 prior to chemotherapy (nab-paclitaxel and gemcitabine) can enhance anti-tumor response by disrupting the fibrotic stroma (“shield”) that typically protects pancreatic tumors, thus improving drug delivery and efficacy. In early clinical results (ACCENT trial), some patients with metastatic pancreatic cancer achieved complete pathological responses, a highly rare event for this disease[3][4][5][6][7].

Other names

narmafotinibnab-paclitaxelgemcitabine